



General Meeting of Shareholders


Telix Pharmaceuticals (ASX:TLX)

10.00am (Sydney time)


5 April 2024



Telix Manufacturing Solutions
in Belgium



TLX250 SPECT image showing uptake
in CAIX-positive lesions



TLX101-CDx PET image showing
uptake in glioblastoma




illustration showing TLX591
binding to PSMA

Important information

The information contained in this presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation may contain forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this presentation together with our risk factors, as disclosed in our most recently filed reports with the ASX or on our website.

To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this presentation, whether as a result of new information, future developments or a change in expectations or assumptions.

Telix’s lead product, Illuccix® (TLX591-CDx) for prostate cancer imaging, has been approved by the Australian Therapeutic Goods Administration (TGA), the U.S. Food and Drug Administration (FDA), and Health Canada. Full United States prescribing information for Illuccix® can be found at <http://illuccixhcp.com/s/illuccix-prescribing-information.pdf>

This presentation has been authorised for release by the Telix Pharmaceuticals Limited Board of Directors. Unless otherwise stated, all figures are in AU\$.

©2024 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals, Illuccix®, Zircaix® and Pixclara™ names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Zircaix® and Pixclara™ are trade names subject to final regulatory approval.



H Kevin McCann AO Chairman



Board of Directors



H Kevin McCann AO

Non-Executive
Director and
Chairman



**Christian
Behrenbruch**

Managing Director
and Group CEO



Tiffany Olson

Non-Executive
Director



Jann Skinner

Non-Executive
Director



Andreas Kluge

Non-Executive
Director



Mark Nelson

Non-Executive
Director

Meeting agenda

- 01** **Chairman's address**
- 02** **CEO's address**
- 03** **Formal items of business,
including voting and questions**

General Meeting of Shareholders

Chairman's address


H Kevin McCann AO



General Meeting of Shareholders

CEO's address

Dr Christian Behrenbruch



TLX250-CDx PET positive scan showing CAIX expression (Phase III ZIRCON study)

Our vision: global leadership in theranostics and precision medicine

Advancing therapeutics, including commencement of Phase III prostate cancer trial

Expanding commercial portfolio, including submission of BLA¹ for Zircaix®²

Enhanced supply chain and manufacturing, European production facility + U.S. clinical dose production

Our transformation over the past 12 months

Revenue \$502.5M in 2023, up 214% on prior year and funding development of late-stage pipeline

Strategic acquisitions adding development capabilities, isotope production and value-add pipeline assets




A global, vertically integrated business

Extensive innovation and manufacturing infrastructure

Equipped to deliver patient doses globally

- Global supply chain
- Isotope production technology
- Radiochemistry and clinical dose production
- Specialist commercial and medical teams



GLOBAL COMMERCIAL, ISOTOPE PROCESSING AND DEVELOPMENT FOOTPRINT

In-house development and production capacity

- End-to-end process development and manufacturing technologies
- U.S. and EU production footprint
- “AlphaLab” for specialty R&D



1. ASX disclosure 5 March 2024. Subject to completion.
2. ASX disclosure 27 February 2024. Subject to completion.
3. Good manufacturing practice.

A strong foundation for growth

R&D investment accelerating progress in four key areas

Progress late-stage therapeutic pipeline

- Phase III ProstACT GLOBAL trial for prostate cancer therapy (TLX591)
- Phase II trials of TLX250 + immunotherapy in ccRCC¹
- Phase II trials exploring CAIX² pan-cancer utility

Advance next-generation radiopharmaceuticals

- Additional trial of alpha therapy candidate for prostate cancer (TLX592)³
- Phase I trial of TLX300-CDx in soft-tissue sarcoma expected to commence in 2024³



Commercialise diagnostics

- Planned launch of Zircaix®⁴ for kidney imaging and Pixclara™⁴ or glioma imaging
- Illuccix® life cycle management
- Geographic expansion of Illuccix®

Vertically integrate supply chain

- Continue to expand U.S. manufacturing footprint
- Enhance in-house process development and production capacity



1. Clear cell renal cell carcinoma.
2. Carbonic anhydrase IX.
3. Subject to regulatory approval.
4. Brand name subject to regulatory approval.

M&A strategy

Scaling-up a complete radiopharmaceutical ecosystem

Adding sought-after resources,
capabilities and value-creating assets

Focus
areas



Supply chain and
manufacturing




Clinical-stage pipeline
expansion



Indication and
franchise expansion

Strategic
rationale

Buy v Build: adding core
capabilities and supply
chain security and
control



Accretive assets in our
key disease focus areas,
with a clear pathway to
revenue generation



Expand commercial
opportunities via
complementary
technologies and skills



Note: ARTMS, IsoTherapeutics and QSAM acquisitions subject to closing.

Accelerating our vertical integration

Adds specialist capabilities and enhances isotope production



Supply chain and
manufacturing



- A commercial-stage radioisotope production technology firm, focus on radio-metals
- Delivers greater reliability and control over diagnostic supply chain, enables margin expansion
- Provides platform for more efficient - and safe - production of high-yield therapeutic radionuclides
- Supports large-scale production of gallium, underpinning second-generation product offering
- Enhances production capacity of Zirconium-89, to support roll-out of Zircaix®¹



- Specialty radiopharmaceutical development, bioconjugation and contract manufacturing firm
- Brings highly-sought after skills in-house, boosting innovation and clinical development capabilities
- U.S. site with GMP cleanrooms, manufacturing and isotope processing capabilities, flexibility to scale
- “Buying” speeds up the expansion of our U.S. manufacturing footprint and establishes a centre of excellence for bioconjugation and isotope processing

QSAM Biosciences acquisition

Highly complementary addition to Telix's therapeutic pipeline




Clinical-stage pipeline expansion

About the Technology

- “Next generation” bone seeking targeted radiopharmaceuticals
- Based on a proven isotope platform for this application: ^{153}Sm (samarium)
- Two major potential applications
 - Palliative / pain management of osteoblastic bone metastases (low dose)
 - Osteosarcoma therapy, including potential application in paediatric osteosarcoma

Synergies

- Highly complementary to our urology franchise
- Adds depth in our focus areas of prostate, brain and sarcoma
- Potential for rapid pathway to commercialisation
- Established reimbursement and patient cost-benefit benchmarks
- Validated manufacturing method and access to established, low-cost supply chain



Whole body SPECT/CT scan of metastatic prostate cancer patient showing bone tumor uptake and continued concentration of ^{153}Sm -DOTMP at bone lesions (brighter areas seen at 48 h). Patient representative scan - individual results may vary.

New technologies add depth in urology

Creating even “stickier” customer relationships




Indication and franchise expansion



- Precision-guided cancer surgery is a fast-growing, high-value field
- The urologist (surgeon) is a key stakeholder: the core Illuccix indications “book end” a surgical procedure
- ~96,000 radical prostatectomies are performed in the U.S. each year¹
>85% of these are performed robotically²



- Differentiated AI-platform with clinical decision support (CDSS) developed for PET/CT imaging
- Potential to harness diagnostic imaging for predictive and prognostic capabilities
- For example, can reliably predict a Gleason score from an Illuccix PET scan³ – this opens potential to new indications for Illuccix®
- Applicable to other disease areas across the pipeline




1. Telix media release 14 June 2022.
2. Harvard Medical School, 2022.


3. L. Papp, et al, “Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga] Ga-PSMA-11 PET/MRI,” *European Journal of Nuclear Medicine and Molecular Imaging*, vol. 48, no. 6, pp. 1795-1805, 2021.

Investment focus leads to key value creating catalysts

Four key areas of investment



Related upcoming milestones



1. Brand name subject to regulatory approval.
2. New drug application.

3. Radiographic progression-free survival.
4. Soft tissue sarcoma.

Thank you